New Health Concerns for Diabetes Drug Actos

Takeda Pharmaceuticals, Inc. diabetes drug Actos has already been linked to an increased risk of bladder cancer. Now, there’s a report in the Archives of Internal Medicine that has shown a connection between Actos and vision loss. Actos, the brand name for pioglitazone,is prescribed to treat Type 2 diabetes (a condition in which the body does not use insulin normally and therefore cannot control the amount of sugar in the blood).
A little less than a year ago, the FDA issued a health warning concerning Actos. The FDA warning noted that diabetes patients who’ve taken Actos for more than a year are at an increased risk of bladder cancer. Two days prior to the FDA warning, Actos was banned in two European countries.
There is already an established Actos MDL (multidistrict litigation)which will handle the numerous Actos side effects lawsuits that have been filed as well as those new Actos lawsuits to be filed in the future. A recent MDL court ruling will allow new Actos lawsuits to be consolidated in the Actos MDL in a quicker, more efficient fashion.